These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27845219)

  • 1. Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial.
    Chen H; Wang F; Yu Z; Zhang Y; Liu C; Dai S; Chen B; Lv J
    Urology; 2017 Feb; 100():59-64. PubMed ID: 27845219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
    Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
    Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder.
    Matsuo T; Miyata Y; Araki K; Mukae Y; Otsubo A; Ohba K; Sakai H
    Low Urin Tract Symptoms; 2020 Jan; 12(1):47-53. PubMed ID: 31407871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
    BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients.
    Dell'Atti L
    Eur Rev Med Pharmacol Sci; 2015; 19(9):1559-63. PubMed ID: 26004592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study.
    Shin DG; Kim HW; Yoon SJ; Song SH; Kim YH; Lee YG; Joo KJ; Bae JH; Kang TW; Jeong SJ; Woo SH; Yoo ES; Son H; Koo KC; Kim SW
    Neurourol Urodyn; 2019 Jan; 38(1):295-304. PubMed ID: 30311691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
    Chapple CR; Amarenco G; López Aramburu MA; Everaert K; Liehne J; Lucas M; Vik V; Ridder A; Snijder R; Yamaguchi O;
    Neurourol Urodyn; 2013 Nov; 32(8):1116-22. PubMed ID: 23424164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders.
    Khusid JA; Weiss JP; Carlsson MO; Mangan EK
    J Urol; 2017 Nov; 198(5):1119-1123. PubMed ID: 28479240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.
    Ohlstein EH; von Keitz A; Michel MC
    Eur Urol; 2012 Nov; 62(5):834-40. PubMed ID: 22695239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vibegron, a Novel Potent and Selective β
    Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
    Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.
    Chapple CR; Abrams P; Andersson KE; Radziszewski P; Masuda T; Small M; Kuwayama T; Deacon S
    J Urol; 2014 Jan; 191(1):253-60. PubMed ID: 24018240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.